Inhibition of MCL-1 by obatoclax sensitizes Sp2/0-Ag14 hybridoma cells to glutamine deprivation-induced apoptosis

Cell Biochemistry and Function

Volumn 33, Issue 5, 2015, Pages 334-340

  Harnett, Curtis C ^a   Abusneina, Abdelmuhsen ^a   Clément, Julie ^a   Gauthier, Eric R ^a  

^a LAURENTIAN UNIVERSITY   (Canada)

Author keywords

Apoptosis; Glutamine; Glutamine addiction; Hybridoma; MCL 1; Nutrient starvation; Obatoclax

Indexed keywords

4 [4 (4' CHLORO 2 BIPHENYLYLMETHYL) 1 PIPERAZINYL] N [4 [3 DIMETHYLAMINO 1 (PHENYLTHIOMETHYL)PROPYLAMINO] 3 NITROBENZENESULFONYL]BENZAMIDE; BH3 PROTEIN; GLUTAMINE; OBATOCLAX; PROTEIN BCL 2; PROTEIN BCL W; PROTEIN BCL XL; PROTEIN MCL 1; ABT-737; BCL2L15 PROTEIN, HUMAN; BIPHENYL DERIVATIVE; MCL1 PROTEIN, HUMAN; NITROPHENOL; PIPERAZINE DERIVATIVE; PYRROLE DERIVATIVE; SULFONAMIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; APOPTOSIS; ARTICLE; B CELL LYMPHOMA; CANCER SURVIVAL; CELL SURVIVAL; CELL VIABILITY; CONTROLLED STUDY; HYBRIDOMA; HYBRIDOMA CELL LINE; LETHAL DOSE; MOUSE; MYELOID CELL LEUKEMIA 1; MYELOID LEUKEMIA; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FAMILY; STARVATION; WESTERN BLOTTING; DEFICIENCY; DRUG EFFECTS; HUMAN; METABOLISM; SENSITIVITY AND SPECIFICITY; TUMOR CELL LINE;

APOPTOSIS; BIPHENYL COMPOUNDS; CELL LINE, TUMOR; CELL SURVIVAL; GLUTAMINE; HUMANS; HYBRIDOMAS; MYELOID CELL LEUKEMIA SEQUENCE 1 PROTEIN; NITROPHENOLS; PIPERAZINES; PROTO-ONCOGENE PROTEINS C-BCL-2; PYRROLES; SENSITIVITY AND SPECIFICITY; SULFONAMIDES;

EID: 84937803100     PISSN: 02636484     EISSN: 10990844     Source Type: Journal    
DOI: 10.1002/cbf.3121     Document Type: Article

References (45)

1. Daye D, Wellen KE. Metabolic reprogramming in cancer: unraveling the role of glutamine in tumorigenesis. Semin Cell Dev Biol 2012; 23: 362-369. doi:10.1016/j.semcdb.2012.02.002.
2. DeBerardinis RJ, Cheng T. Q's next: the diverse functions of glutamine in metabolism, cell biology and cancer. Oncogene 2010; 29: 313-324. doi:10.1038/onc.2009.358.
3. DeBerardinis RJ, Mancuso A, Daikhin E, et al. Beyond aerobic glycolysis: transformed cells can engage in glutamine metabolism that exceeds the requirement for protein and nucleotide synthesis. Proc Natl Acad Sci U S A 2007; 104: 19345-19350. doi:10.1073/pnas.0709747104.
4. Wise DR, Thompson CB. Glutamine addiction: a new therapeutic target in cancer. Trends Biochem Sci 2010; 35: 427-433. doi:10.1016/j.tibs.2010.05.003.
5. Eagle H, Oyama VI, Levy M, Horton CL, Fleischman R. The growth response of mammalian cells in tissue culture to L-glutamine and L-glutamic acid. J Biol Chem 1956; 218: 607-616.
6. Mates JM, Segura JA, Martin-Rufian M, Campos-Sandoval JA, Alonso FJ, Marquez J. Glutaminase isoenzymes as key regulators in metabolic and oxidative stress against cancer. Curr Mol Med 2013; 13: 514-534.
7. Fuchs BC, Bode BP. Stressing out over survival: glutamine as an apoptotic modulator. J Surg Res 2006; 131: 26-40. doi:10.1016/j.jss.2005.07.013.
8. Charbonneau JR, Gauthier ER. Prolongation of murine hybridoma cell survival in stationary batch culture by Bcl-xL expression. Cytotechnology 2000; 34: 131-139. doi:10.1023/A:1008186302600.
9. Ryder C, McColl K, Zhong F, Distelhorst CW. Acidosis promotes Bcl-2 family-mediated evasion of apoptosis: involvement of acid-sensing G protein-coupled receptor Gpr65 signaling to Mek/Erk. J Biol Chem 2012; 287: 27863-27875. doi:10.1074/jbc.M112.384685.
10. Yuneva M, Zamboni N, Oefner P, Sachidanandam R, Lazebnik Y. Deficiency in glutamine but not glucose induces MYC-dependent apoptosis in human cells. J Cell Biol 2007; 178: 93-105. doi:10.1083/jcb.200703099.
11. Czabotar PE, Lessene G, Strasser A, Adams JM. Control of apoptosis by the BCL-2 protein family: implications for physiology and therapy. Nat Rev Mol Cell Biol 2014; 15: 49-63. doi:10.1038/nrm3722.
12. Youle RJ, Strasser A. The BCL-2 protein family: opposing activities that mediate cell death. Nat Rev Mol Cell Biol 2008; 9: 47-59. doi:10.1038/nrm2308.
13. Thomas LW, Lam C, Edwards SW. Mcl-1; the molecular regulation of protein function. FEBS Lett 2010; 584: 2981-2989. doi:10.1016/j.febslet.2010.05.061.
14. Willimott S, Wagner SD. Post-transcriptional and post-translational regulation of Bcl2. Biochem Soc Trans 2010; 38: 1571-1575. doi:10.1042/BST0381571.
15. Deverman BE, Cook BL, Manson SR, et al. Bcl-xL deamidation is a critical switch in the regulation of the response to DNA damage. Cell 2002; 111: 51-62.
16. Kirsch DG, Doseff A, Chau BN, et al. Caspase-3-dependent cleavage of Bcl-2 promotes release of cytochrome c. J Biol Chem 1999; 274: 21155-21161.
17. Mojsa B, Lassot I, Desagher S. Mcl-1 ubiquitination: unique regulation of an essential survival protein. Cells 2014; 3: 418-437. doi:10.3390/cells3020418.
18. Perreault J, Lemieux R. Rapid apoptotic cell death of B-cell hybridomas in absence of gene expression. J Cell Physiol 1993; 156: 286-293. doi:10.1002/jcp.1041560210.
19. Paquette JC, Guerin PJ, Gauthier ER. Rapid induction of the intrinsic apoptotic pathway by L-glutamine starvation. J Cell Physiol 2005; 202: 912-921. doi:10.1002/jcp.20194.
20. Gauthier ER, Piche L, Lemieux G, Lemieux R. Role of bcl-X(L) in the control of apoptosis in murine myeloma cells. Cancer Res 1996; 56: 1451-1456.
21. Perciavalle RM, Stewart DP, Koss B, et al. Anti-apoptotic MCL-1 localizes to the mitochondrial matrix and couples mitochondrial fusion to respiration. Nat Cell Biol 2012; 14: 575-583. doi:10.1038/ncb2488.
22. Bingle CD, Craig RW, Swales BM, Singleton V, Zhou P, Whyte MK. Exon skipping in Mcl-1 results in a bcl-2 homology domain 3 only gene product that promotes cell death. J Biol Chem 2000; 275: 22136-22146. doi:10.1074/jbc.M909572199.
23. Bae J, Leo CP, Hsu SY, Hsueh AJ. MCL-1S, a splicing variant of the antiapoptotic BCL-2 family member MCL-1, encodes a proapoptotic protein possessing only the BH3 domain. J Biol Chem 2000; 275: 25255-25261. doi:10.1074/jbc.M909826199.
24. Soleymanlou N, Jurisicova A, Wu Y, et al. Hypoxic switch in mitochondrial myeloid cell leukemia factor-1/Mtd apoptotic rheostat contributes to human trophoblast cell death in preeclampsia. Am J Pathol 2007; 171: 496-506. doi:10.2353/ajpath.2007.070094.
25. Herrant M, Jacquel A, Marchetti S, et al. Cleavage of Mcl-1 by caspases impaired its ability to counteract Bim-induced apoptosis. Oncogene 2004; 23: 7863-7873. doi:10.1038/sj.onc.1208069.
26. Weng C, Li Y, Xu D, Shi Y, Tang H. Specific cleavage of Mcl-1 by caspase-3 in tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in Jurkat leukemia T cells. J Biol Chem 2005; 280: 10491-10500. doi:10.1074/jbc.M412819200.
27. Chauhan D, Velankar M, Brahmandam M, et al. A novel Bcl-2/Bcl-X(L)/Bcl-w inhibitor ABT-737 as therapy in multiple myeloma. Oncogene 2007; 26: 2374-2380. doi:10.1038/sj.onc.1210028.
28. Oltersdorf T, Elmore SW, Shoemaker AR, et al. An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature 2005; 435: 677-681. doi:10.1038/nature03579.
29. Nguyen M, Marcellus RC, Roulston A, et al. Small molecule obatoclax (GX15-070) antagonizes MCL-1 and overcomes MCL-1-mediated resistance to apoptosis. Proc Natl Acad Sci U S A 2007; 104: 19512-19517. doi:10.1073/pnas.0709443104.
30. Zhai D, Jin C, Satterthwait AC, Reed JC. Comparison of chemical inhibitors of antiapoptotic Bcl-2-family proteins. Cell Death Differ 2006; 13: 1419-1421. doi:10.1038/sj.cdd.4401937.
31. Meynet O, Beneteau M, Jacquin MA, et al. Glycolysis inhibition targets Mcl-1 to restore sensitivity of lymphoma cells to ABT-737-induced apoptosis. Leukemia 2012; 26: 1145-1147. doi:10.1038/leu.2011.327.
32. Heidari N, Hicks MA, Harada H. GX15-070 (obatoclax) overcomes glucocorticoid resistance in acute lymphoblastic leukemia through induction of apoptosis and autophagy. Cell Death Dis 2010; 1: e76. doi:10.1038/cddis.2010.53.
33. Martinez-Paniagua MA, Baritaki S, Huerta-Yepez S, et al. Mcl-1 and YY1 inhibition and induction of DR5 by the BH3-mimetic obatoclax (GX15-070) contribute in the sensitization of B-NHL cells to TRAIL apoptosis. Cell Cycle 2011; 10: 2792-2805.
34. Huang CR, Yang-Yen HF. The fast-mobility isoform of mouse Mcl-1 is a mitochondrial matrix-localized protein with attenuated anti-apoptotic activity. FEBS Lett 2010; 584: 3323-3330. doi:10.1016/j.febslet.2010.07.013.
35. Mahajan IM, Chen MD, Muro I, Robertson JD, Wright CW, Bratton SB. BH3-only protein BIM mediates heat shock-induced apoptosis. PLoS One 2014; 9: e84388. doi:10.1371/journal.pone.0084388.
36. Pang X, Zhang J, Lopez H, et al. The carboxyl-terminal tail of Noxa protein regulates the stability of Noxa and Mcl-1. J Biol Chem 2014; 289: 17802-17811. doi:10.1074/jbc.M114.548172.
37. Kobayashi S, Lee SH, Meng XW, et al. Serine 64 phosphorylation enhances the antiapoptotic function of Mcl-1. J Biol Chem 2007; 282: 18407-18417. doi:10.1074/jbc.M610010200.
38. Thomas LW, Lam C, Clark RE, et al. Serine 162, an essential residue for the mitochondrial localization, stability and anti-apoptotic function of Mcl-1. PLoS One 2012; 7: e45088. doi:10.1371/journal.pone.0045088.
39. Faber AC, Coffee EM, Costa C, et al. mTOR inhibition specifically sensitizes colorectal cancers with KRAS or BRAF mutations to BCL-2/BCL-XL inhibition by suppressing MCL-1. Cancer Discov 2014; 4: 42-52. doi:10.1158/2159-8290.CD-13-0315.
40. Zang C, Eucker J, Liu H, Muller A, Possinger K, Scholz CW. Concurrent inhibition of PI3-kinase and mTOR induces cell death in diffuse large B cell lymphomas, a mechanism involving down regulation of Mcl-1. Cancer Lett 2013; 339: 288-297. doi:10.1016/j.canlet.2012.11.013.
41. Koo J, Yue P, Deng X, Khuri FR, Sun SY. mTOR complex 2 stabilizes Mcl-1 protein by suppressing its GSK3-dependent and SCF-FBXW7-mediated degradation. Mol Cell Biol 2015. doi:10.1128/MCB.01525-14.
42. Duran RV, Oppliger W, Robitaille AM, et al. Glutaminolysis activates Rag-mTORC1 signaling. Mol Cell 2012; 47: 349-358. doi:10.1016/j.molcel.2012.05.043.
43. Hensley CT, Wasti AT, DeBerardinis RJ. Glutamine and cancer: cell biology, physiology, and clinical opportunities. J Clin Invest 2013; 123: 3678-3684. doi:10.1172/JCI69600.
44. Zhao Y, Butler EB, Tan M. Targeting cellular metabolism to improve cancer therapeutics. Cell Death Dis 2013; 4: e532. doi:10.1038/cddis.2013.60.
45. Olsen RR, Mary-Sinclair MN, Yin Z, Freeman KW. Antagonizing Bcl-2 family members sensitizes neuroblastoma and Ewing's sarcoma to an inhibitor of glutamine metabolism. PLoS One 2015; 10: e0116998. doi:10.1371/journal.pone.0116998.